Tegucigalpa, Sep 28 (EFE) .- Early detection is key to reducing deaths from breast cancer in Honduras, where some 400 women die each year from this disease, which affects one in eight, the Honduran Foundation said on Wednesday. against Breast Cancer (Funhocam).
Breast cancer is a “lethal disease” and in Honduras it is the cancer that most affects women, Karen Mendoza, a member of the Funhocam board of directors, told Efe during the launch of an awareness campaign about this disease.
He noted that when cancer is detected in the early stages, the patient has a 98% chance of being cured.
Mendoza indicated that in Honduras late detection is very common, so it is necessary to reduce these times to save the life of a woman.
Women “are not going to get checked or they are simply very afraid of having a mammogram because it will hurt, but what matters is detecting (the disease) in time,” he explained.
Every year some 400 women die in Honduras from breast cancer, according to records from various health sources.
Mendoza emphasized that preventive check-ups are key to reducing the mortality rate and the cost of treatment.
He added that mammography is the “most accurate test to detect cancer”, so he recommended that women get it done from the age of 40.
In 2020, Honduras registered a total of 5,443 new cases of cancer in women, of which 1,285 correspond to breast cancer, according to figures cited by Funhocam.
The expert highlighted that every day only the Honduran foundation diagnoses three new cases of breast cancer.
In the last 14 years, Funhocam has treated 48,239 patients and has performed 18,261 mammograms for low-income women free of charge.
The cost of treating breast cancer is between 500,000 lempiras and 1.5 million lempiras (between 20,296 and 60,889 dollars).
Within the framework of the World Day for the fight against breast cancer, which is commemorated every October 19, the Funhocam launched this Wednesday the campaign “Your fight, my fight”, to sensitize women in the early detection programs of the breast cancer and report the risk factors for the disease. EFE
� EFE 2022. The redistribution and redistribution of all or part of the contents of EFE services is expressly prohibited, without the prior and express consent of Agencia EFE SA